80
Participants
Start Date
April 8, 2015
Primary Completion Date
January 21, 2020
Study Completion Date
November 17, 2022
CTL019
Tisagenlecleucel was administered as a single iv infusion. Dose: 2.0 to 5.0x10\^6 tisagenlecleucel per kg body weight (for patients ≤ 50 kg) or 1.0 to 2.5x10\^8 tisagenlecleucel (for patients \>50 kg).
Novartis Investigative Site, Parkville
Novartis Investigative Site, Ghent
The Childrens Hospital of Philadelphia CHOP, Philadelphia
Novartis Investigative Site, Monza
Duke Unversity Medical Center ., Durham
Children's Healthcare of Atlanta SC CTL019, Atlanta
University of Minnesota, Minneapolis
Novartis Investigative Site, Frankfurt
Children s Mercy Hospital SC - CTL019B2205J, Kansas City
Novartis Investigative Site, Paris
University of Texas Southwestern Medical Center ., Dallas
Novartis Investigative Site, Paris
University of Utah Clinical Trials Office SC - CTL019B2205J, Salt Lake City
Childrens Hospital Los Angeles SC CTL019, Los Angeles
Stanford Universtiy Medical Center SC - CTL019B2205J - B2206, Stanford
University of Michigan ., Ann Arbor
Oregon Health and Science University Doernbecher Children's Hosp., Portland
Novartis Investigative Site, Vienna
Novartis Investigative Site, Toronto
Novartis Investigative Site, Montreal
Novartis Investigative Site, Kyoto
Novartis Investigative Site, Oslo
Novartis Investigative Site, Esplugues de Llobregat
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY